Back to clinical trials list

PEACE 7

A randomised Phase III trial with a factorial design evaluating the efficacy and safety of darolutamide and stereotactic dose escalated radiotherapy in patients with localised prostate cancer and high-risk features of relapse, from the Prostate Cancer Consortium in Europe (PEACE).
  • Open at Paris since : 21/07/2025
  • Open at Saint-Cloud since : 08/10/2025
  • Target : Adult
  • Phase : Phase III

Trial description

Primary endpoint (estimated):;Metastasis-free survival (MFS) À time from randomization to detection of metastasis or death.;Secondary endpoints (estimated):;Progression-free survival (PFS), clinical or biochemical;Overall survival (OS);Safety/tolerability and adverse events;Quality of life assessments;Time to next systemic therapy or symptomatic skeletal events
Url of the trial

Main investigators

GILLES CREHANGE

Professeur - Médecin

Contact